State of Alaska Department of Revenue Has $502,000 Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

State of Alaska Department of Revenue lifted its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 5.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,892 shares of the company’s stock after acquiring an additional 1,111 shares during the period. State of Alaska Department of Revenue’s holdings in Amphastar Pharmaceuticals were worth $502,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock valued at $39,000 after acquiring an additional 424 shares during the period. Hohimer Wealth Management LLC raised its position in shares of Amphastar Pharmaceuticals by 6.9% in the 1st quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company’s stock valued at $232,000 after acquiring an additional 520 shares during the period. Signaturefd LLC raised its position in shares of Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock valued at $25,000 after acquiring an additional 520 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Amphastar Pharmaceuticals by 13.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company’s stock valued at $139,000 after acquiring an additional 580 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after acquiring an additional 613 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH opened at $25.98 on Thursday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $53.96. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The firm has a fifty day simple moving average of $27.56 and a 200 day simple moving average of $25.50. The stock has a market capitalization of $1.21 billion, a PE ratio of 9.73 and a beta of 0.75.

Analysts Set New Price Targets

A number of analysts recently issued reports on AMPH shares. Needham & Company LLC raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research note on Tuesday, August 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. Finally, Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.